Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same
Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.
1. A method of treating or ameliorating osteoarthritis, the method comprising administering an effective amount of a pharmaceutical composition to a patient in need thereof;
the pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) compound in an amount sufficient to allow stem cells in the patient to differentiate into an osteocyte cell of osteoblast lineage, or into a chondrocyte cell of chondroblast lineage; and a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant;
wherein the PPAR compound has a structural formula of Formula I:
X is O;
R is CH═CHR 3 , and R 3 is carboxylic acid; and,
R 1 is para CF 3 and R 2 is meta H; or R 1 is meta CF 3 and R 2 is para H; and
salts, isomers, stereoisomers, enantiomers, racemates, solvates, hydrates, polymorphs, and prodrugs thereof.
2. The method of claim 1 , wherein the administration of the pharmaceutical composition is by surgical implantation into the patient.
3. The method of claim 1 , wherein the administration comprises treating isolated mammalian stem cells with an effective amount of the pharmaceutical composition, and administering the treated mammalian stem cells to the patient.
4. The method of claim 1 , wherein the administration comprises intravenous administration of the pharmaceutical compound to the patient.
5. The method of claim 1 , wherein the administration comprises subcutaneous administration of the pharmaceutical compound to the patient.